Bristol myers squibb co (BMY)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09Sep'08Jun'08
Revenues

10,781

7,945

6,007

6,273

5,920

5,973

5,691

5,704

5,193

5,449

5,254

5,144

4,929

5,243

4,922

4,871

4,391

4,287

4,069

4,163

4,041

4,258

3,921

3,889

3,811

4,441

4,065

4,048

3,831

4,191

3,736

4,443

5,251

5,454

5,345

5,434

5,011

5,111

4,798

4,768

4,807

5,033

4,788

4,665

4,322

5,254

5,203

Cost of Goods and Services Sold

3,662

2,452

1,810

1,992

1,824

1,610

1,648

1,625

1,584

1,601

1,579

1,569

1,265

1,406

1,305

1,206

1,052

952

1,097

1,013

847

966

1,007

991

968

1,273

1,175

1,108

1,063

1,075

987

1,245

1,303

1,367

1,407

1,481

1,343

1,414

1,280

1,277

1,306

1,433

1,317

1,225

1,165

1,634

1,670

Selling, General and Administrative Expense

1,606

1,734

1,055

1,076

1,006

1,336

1,104

1,131

980

1,316

1,163

1,187

1,085

1,529

1,144

1,238

1,068

1,501

1,176

1,135

1,029

1,885

1,029

951

957

1,923

980

1,042

994

1,143

1,071

1,004

1,002

1,216

1,019

1,040

928

1,000

892

894

900

1,170

953

922

901

1,208

1,165

Advertising and product promotion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

171

187

163

-

194

218

189

212

167

224

194

285

205

253

214

271

231

263

212

334

256

298

248

362

420

Research and Development Expense

2,372

2,090

1,382

1,328

1,348

1,367

1,280

2,435

1,250

1,925

1,561

1,679

1,303

1,472

1,138

1,266

1,136

1,916

1,132

1,856

1,016

1,189

983

1,416

946

957

893

951

930

1,082

951

962

909

1,008

973

923

935

1,010

824

822

910

1,108

820

811

908

834

826

Amortization of Acquired Intangible Assets

2,282

-

-

-

24

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment charge for BMS-986094 intangible asset

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,830

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

32

Provision for restructuring

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8

40

44

-

15

24

11

47

51

19

19

26

30

Litigation expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

22

-

-

0

0

28

104

30

2

Equity in net income of affiliates

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71

62

82

-

70

85

97

115

139

150

146

164

150

Other Nonoperating (Income) Expense

-1,163

-687

-411

-101

261

-58

508

4

400

188

232

586

679

250

224

454

520

-328

323

-107

299

-799

277

104

208

-20

-5

-199

19

-166

11

51

184

139

26

31

138

177

10

19

-113

264

35

10

72

-169

13

Costs and Expenses

11,085

8,074

4,658

4,497

3,941

4,468

3,524

5,187

3,414

4,751

4,071

3,849

2,974

4,157

3,363

3,256

2,736

4,697

3,082

4,111

2,593

4,318

2,913

3,441

2,826

3,572

3,247

3,518

3,157

3,678

4,995

3,384

3,224

3,860

3,515

3,644

3,244

3,698

3,184

3,176

3,355

3,713

3,223

3,143

3,127

4,099

3,982

Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest

-304

-129

1,349

1,776

1,979

1,505

2,167

517

1,779

698

1,183

1,295

1,955

1,086

1,559

1,615

1,655

-410

987

52

1,448

-60

1,008

448

985

869

818

530

674

513

-1,259

1,059

2,027

1,594

1,830

1,790

1,767

1,413

1,614

1,592

1,452

1,320

1,565

1,522

1,195

1,155

1,221

Income Tax Expense (Benefit)

462

931

-17

337

264

347

255

135

284

3,027

327

373

429

188

344

427

449

-222

257

162

249

-87

276

114

49

134

126

0

51

-411

-546

251

545

363

475

483

400

571

312

324

351

188

366

353

275

308

258

Net Earnings from Continuing Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,132

1,199

1,169

920

847

963

Earnings, net of taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

64

91

129

1

-

42

Gain on disposal, net of taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,157

0

0

0

-

0

Net Earnings from Discontinued Operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,221

91

129

1

1,990

42

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-766

-1,060

1,366

1,439

1,715

1,158

1,912

382

1,495

-2,329

856

922

1,526

898

1,215

1,188

1,206

-188

730

-110

1,199

27

732

334

936

735

692

530

623

924

-713

808

1,482

1,231

1,355

1,307

1,367

842

1,302

1,268

1,101

8,353

1,290

1,298

921

2,837

1,005

Net Income (Loss) Attributable to Noncontrolling Interest

9

-4

13

7

5

-2

11

9

9

-1

11

6

-48

4

13

22

11

9

24

20

13

14

11

1

-1

9

0

-6

14

-1

-2

163

381

379

386

405

381

359

353

341

358

328

324

315

283

259

241

Net Income (Loss) Attributable to Parent

-775

-1,056

1,353

1,432

1,710

1,160

1,901

373

1,486

-2,328

845

916

1,574

894

1,202

1,166

1,195

-197

706

-130

1,186

13

721

333

937

726

692

536

609

925

-711

645

1,101

852

969

902

986

483

949

927

743

8,025

966

983

638

2,578

764

Earnings Per Share [Abstract]
Net earnings from continuing operations attributable to Bristol-Myers Squibb Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

818

892

880

649

-

-

Net earnings from discontinued operations attributable to Bristol-Myers Squibb Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,207

74

103

-11

-

-

Net Earnings Attributable to Bristol-Myers Squibb Company

-775

-1,056

1,353

1,432

1,710

1,160

1,901

373

1,486

-2,328

845

916

1,574

-

1,202

1,166

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

966

983

638

2,578

764

Basic Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.41

0.45

0.44

0.33

0.30

0.36

Diluted Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.41

0.45

0.44

0.33

0.29

0.36

Earnings Per Share, Basic

-0.34

-0.74

0.83

0.88

1.05

0.71

1.16

0.23

0.91

-1.42

0.52

0.56

0.95

0.53

0.72

0.70

0.72

-0.11

0.42

-0.08

0.71

0.01

0.43

0.20

0.57

0.44

0.42

0.33

0.37

0.57

-0.43

0.38

0.65

0.50

0.57

0.53

0.58

0.28

0.55

0.54

0.43

4.05

0.49

0.49

0.32

1.30

0.38

Earnings Per Share, Diluted

-0.34

-0.73

0.83

0.87

1.04

0.71

1.16

0.23

0.91

-1.40

0.51

0.56

0.94

0.53

0.72

0.69

0.71

-0.12

0.42

-0.08

0.71

0.01

0.43

0.20

0.56

0.43

0.42

0.32

0.37

0.57

-0.43

0.38

0.64

0.51

0.56

0.52

0.57

0.28

0.55

0.53

0.43

4.05

0.48

0.49

0.32

1.28

0.38

Cash dividends declared per common share

-

-

-

-

-

-

-

-

-

-

0.39

0.39

0.39

-

0.38

0.38

0.38

0.38

0.37

0.37

0.37

0.37

0.36

0.36

0.36

0.36

0.35

0.35

0.35

0.35

0.34

0.34

0.34

0.34

0.33

0.33

0.33

0.33

0.32

0.32

0.32

0.32

0.31

0.31

0.31

0.31

0.31

Net product sales [Member]
Revenues

10,541

7,662

5,768

6,031

5,713

5,715

5,433

5,461

4,972

5,046

4,862

4,770

4,580

4,814

4,492

4,432

3,964

3,862

3,552

3,572

3,059

3,240

2,843

2,770

2,807

3,298

3,025

3,024

2,957

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Alliance and other revenues [Member]
Revenues

240

283

239

242

207

258

258

243

221

403

392

374

349

429

430

439

427

425

517

591

982

1,018

1,078

1,119

1,004

1,143

1,040

1,024

874

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-